- Home
- GHRS vs PRAX Comparison
GHRS vs PRAX Comparison
Compare GHRS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- PRAX
- Stock Information
- Founded
- GHRS 2018
- PRAX 2015
- Country
- GHRS Ireland
- PRAX United States
- Employees
- GHRS N/A
- PRAX N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- PRAX Health Care
- Exchange
- GHRS Nasdaq
- PRAX Nasdaq
- Market Cap
- GHRS 583.1M
- PRAX 599.7M
- IPO Year
- GHRS 2021
- PRAX 2020
- Fundamental
- Price
- GHRS $12.03
- PRAX $38.55
- Analyst Decision
- GHRS Strong Buy
- PRAX Strong Buy
- Analyst Count
- GHRS 8
- PRAX 10
- Target Price
- GHRS $30.63
- PRAX $116.50
- AVG Volume (30 Days)
- GHRS 149.3K
- PRAX 320.6K
- Earning Date
- GHRS 05-08-2025
- PRAX 05-02-2025
- Dividend Yield
- GHRS N/A
- PRAX N/A
- EPS Growth
- GHRS N/A
- PRAX N/A
- EPS
- GHRS N/A
- PRAX N/A
- Revenue
- GHRS N/A
- PRAX $8,122,000.00
- Revenue This Year
- GHRS N/A
- PRAX N/A
- Revenue Next Year
- GHRS N/A
- PRAX N/A
- P/E Ratio
- GHRS N/A
- PRAX N/A
- Revenue Growth
- GHRS N/A
- PRAX 270.02
- 52 Week Low
- GHRS $6.00
- PRAX $26.70
- 52 Week High
- GHRS $20.50
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- GHRS 58.82
- PRAX 53.72
- Support Level
- GHRS $10.66
- PRAX $35.21
- Resistance Level
- GHRS $13.00
- PRAX $38.90
- Average True Range (ATR)
- GHRS 0.96
- PRAX 2.09
- MACD
- GHRS 0.12
- PRAX 0.07
- Stochastic Oscillator
- GHRS 67.84
- PRAX 69.58
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.